drugset / Trial / NCT06121843
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).
Timeline
- Start
- 2024-02-22
- Primary completion
- 2028-08-01
- Completion
- 2028-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alnuctamab | Protein / enzyme biologic | — | — |
| Subject | Arlocabtagene Autoleucel | Unknown | — | — |
| Subject | Elranatamab | Monoclonal antibody | — | — |
| Subject | Iberdomide | Small molecule | — | — |
| Subject | Mezigdomide | Small molecule | — | — |
| Background | Dexamethasone | Small molecule | — | — |